Search Results - "Rayes, B"

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) by Prajapati, H.J., Spivey, J.R., Hanish, S.I., El-Rayes, B.F., Kauh, J.S., Chen, Z., Kim, H.S.

“…We analyzed the magnetic resonance imaging (MRI) responses by world health organization (WHO), response evaluation criteria in solid tumor (RECIST), European…”
Get full text

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours by Papadopoulos, K P, El-Rayes, B F, Tolcher, A W, Patnaik, A, Rasco, D W, Harvey, R D, LoRusso, P M, Sachdev, J C, Abbadessa, G, Savage, R E, Hall, T, Schwartz, B, Wang, Y, Kazakin, J, Shaib, W L

“…Background: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and…”
Get full text

Targeting the epidermal growth factor receptor by EL-RAYES, B. F, LORUSSO, P. M

“…The epidermal growth factor receptor (EGFR) is a member of the erbB family of tyrosine kinase receptors (RTK). The EGFR is involved in cell proliferation,…”
Get full text

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 by Melero, I, Yau, T, Kang, Y-K, Kim, T-Y, Santoro, A, Sangro, B, Kudo, M, Hou, M-M, Matilla, A, Tovoli, F, Knox, J, He, A R, El-Rayes, B, Acosta-Rivera, M, Lim, H Y, Soleymani, S, Yao, J, Neely, J, Tschaika, M, Hsu, C, El-Khoueiry, A B

“…Nivolumab plus ipilimumab demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma…”
Get more information

A Phase II multi institutional study of nivolumab in patients with advanced refractory biliary tract cancers (BTC) by Kim, R., Kim, D., Alese, O., Li, D., El-Rayes, B., Shah, N., Schell, M., Zhou, J., Chung, V.

Get full text

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers by El-Rayes, B.F., Zalupski, M., Bekai-Saab, T., Heilbrun, L.K., Hammad, N., Patel, B., Urba, S., Shields, A.F., Vaishampayan, U., Dawson, S., Almhanna, K., Smith, D., Philip, P.A.

“…Background: Bevacizumab has demonstrated antitumor activity in multiple diseases. This phase II study was undertaken to determine the effects of adding…”
Get full text

Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin by Kim, H, Camacho, J, Kokabi, N, El-Rayes, B

Get full text

A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts) by Bekaii-Saab, T., Starodub, A., El-Rayes, B., O’Neil, B., Shahda, S., Ciombor, K., Noonan, A., Hanna, W., Sehdev, A., Shaib, W., Mikhail, S., Neki, A., Oh, C., Li, Y.Z., Li, W., Borodyansky, L., Li, C.J.

Get full text

Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Akce, M., Kissick, H., Carthon, B.C., Shaib, W.L., Alese, O.B., Steuer, C.E., Wu, C., Lawson, D.H., Kudchadkar, R., Master, V., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D.

Get full text

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Martini, D.J., Shabto, J.M., Liu, Y., Khan, A.I., Williams, M.A., Lewis, C., Collins, H.H., Kissick, H., Carthon, B.C., Akce, M., Shaib, W.L., Alese, O.B., Lawson, D.H., Kudchadkar, R., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D., Master, V.A.

Get full text

PD-019ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) by Mazzaferro, V, Shaib, W, Rimassa, L, Harris, W, Personeni, N, El-Rayes, B, Tolcher, A, Hall, T, Wang, Y, Schwartz, B, Kazakin, J, Droz Dit Busset, M, Cotsoglou, C, Papadopoulos, K

Get full text

Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer by Hall, W A, Petrova, A V, Colbert, L E, Hardy, C W, Fisher, S B, Saka, B, Shelton, J W, Warren, M D, Pantazides, B G, Gandhi, K, Kowalski, J, Kooby, D A, El-Rayes, B F, Staley, C A, Volkan Adsay, N, Curran, W J, Landry, J C, Maithel, S K, Yu, D S

“…The DNA damage response (DDR) promotes genome integrity and serves as a cancer barrier in precancerous lesions but paradoxically may promote cancer survival…”
Get full text

Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045) by Garg, M.K, Zhao, F, Lee, J, Sparano, J, Palefsky, J, Henry, D, Wachsman, W, Rajdev, L, Aboulafia, D, Mitchell, E, Onitilo, A, El-Rayes, B, Nabbout, N, Fitzgerald, T, Mitsuyasu, R, Benson, A.B, Kachnic, L.A

Get full text

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies by Harvey, R D, Owonikoko, T K, Lewis, C M, Akintayo, A, Chen, Z, Tighiouart, M, Ramalingam, S S, Fanucchi, M P, Nadella, P, Rogatko, A, Shin, D M, El-Rayes, B, Khuri, F R, Kauh, J S

“…Background: This phase 1 trial utilising a Bayesian continual reassessment method evaluated bortezomib and sunitinib to determine the maximum tolerated dose…”
Get full text

Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: surveillance, epidemiology and end results database vs. tertiary cancer center by Xing, M, Prajapati, H.J, Kokabi, N, Camacho, J.C, El-Rayes, B, Kim, H.S

Get full text

Prospective open-label single center study of safety and efficacy of glass-based Y90 radioembolization for infiltrative HCC with PVT by Kokabi, N, Camacho, J.C, Xing, M, El-Rayes, B, Kauh, J, Kim, H.S

Get full text

Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma and the effect of resin-based Yttrium-90 radioembolization: surveillance, epidemiology and end results database vs. tertiary cancer center by Xing, M, Kokabi, N, Camacho, J.C, El-Rayes, B, Kim, H.S

Get full text

Molecular Mechanisms Underlying the Divergent Roles of SPARC in Human Carcinogenesis by Nagaraju, Ganji Purnachandra, Dontula, Ranadheer, Bassel, El-Rayes F., Lakka, Sajani S

“…Communication between the cell and its surrounding environment, consisting of proteinaceous (non-living material) and extracellular matrix (ECM), is important…”
Get full text

The therapeutic dilemma of BCLC C hepatocellular carcinoma (HCC): an interventional oncology-based approach by Camacho, J.C, Spivey, J.R, Hanish, S.I, El-Rayes, B, Kauh, J, Kim, H.S

“…Learning Objectives Discuss treatment impact of image-guided interventions and present a practical algorithm to select-treat patients with advanced HCC…”
Get full text

Survivals and predictive factors of atypical unresectable hepatocellular carcinoma (MHCC) treated with doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) by Prajapati, H.J, Spivey, J.R, Hanish, S.I, El-Rayes, B, Kauh, J, Kim, H.S

“…Purpose To investigate the survivals of patients (pts) with atypical HCC treated with DEB TACE. Materials and Methods Pretreatment contrast enhanced dynamic…”
Get full text